Fol­low­ing can­cer com­bo deal with Bris­tol-My­ers, Taris gets $25M Se­ries B

Just one day af­ter an­nounc­ing a can­cer com­bo col­lab­o­ra­tion with Bris­tol-My­ers Squibb, Taris Bio­med­ical has raised $25 mil­lion in a new Se­ries B round backed in part by the phar­ma gi­ant.

Some of that new cash will be used to take the com­pa­ny’s lead pro­gram, called TAR-200, through ear­ly clin­i­cal tri­als. TAR-200 has been de­signed to re­lease gem­c­itabine, a chemother­a­peu­tic agent, in the blad­der con­tin­u­ous­ly over sev­en days.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.